Skip to main content
. Author manuscript; available in PMC: 2012 Feb 13.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2010 Oct 9;38(2):334–342. doi: 10.1007/s00259-010-1633-8

Fig. 3.

Fig. 3

Therapeutic ratio corresponding to 3F8 labeled with different isotopes. Half life, percent immunoreactivity, and specific activity were varied as detailed in a. a Specific activity, immunoreactivity and half life for radiolabeled 3F8. b Therapeutic ratio corresponding to 3F8 labeled with different isotopes